52-53-9
52-53-9
Chemical Structure
Verapamil
Synonym(s): (±)-Verapamil; CP-16533-1
- CAS No.: 52-53-9
- Formula:C27H38N2O4
- Molecular Weight:454.60
IUPAC Name: 5-((3,4-dimethoxyphenethyl)(methyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile
InChIKey: SGTNSNPWRIOYBX-UHFFFAOYSA-N
SMILES: COC1=CC=C(C(C#N)(C(C)C)CCCN(CCC2=CC=C(OC)C(OC)=C2)C)C=C1OC
Biological Activity: Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Verapamil | 99.88% | Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Verapamil (Standard) | 99.72% | Verapamil (Standard) is the analytical standard of Verapamil. This product is intended for research and analytical applications. Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(Rac)-Verapamil-d7 (hydrochloride) | (Rac)-Verapamil-d7 (hydrochloride) is the deuterium labeled (Rac)-Verapamil. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Verapamil-d3 | Verapamil-d3 ((±)-Verapamil-d3) is deuterium labeled Verapamil. Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Verapamil-d6 | Verapamil-d6 ((±)-Verapamil-d6) is deuterium labeled Verapamil. Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Verapamil-d7 | Verapamil-d7 is the deuterium labeled Verapamil (HY-14275). Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Gowarty JL, et al. Verapamil as a culprit of palbociclib toxicity. J Oncol Pharm Pract. 2019 Apr;25(3):743-746. [Content Brief]
- [2]. Krikler DM. Verapamil in arrhythmia. Br J Clin Pharmacol. 1986;21 Suppl 2:183S-189S. [Content Brief]
- [3]. Rehnqvist N,et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J. 1996 Jan;17(1):76-81. [Content Brief]
